MA30348B1 - Diagnostics et traitements de tumeurs - Google Patents

Diagnostics et traitements de tumeurs

Info

Publication number
MA30348B1
MA30348B1 MA31315A MA31315A MA30348B1 MA 30348 B1 MA30348 B1 MA 30348B1 MA 31315 A MA31315 A MA 31315A MA 31315 A MA31315 A MA 31315A MA 30348 B1 MA30348 B1 MA 30348B1
Authority
MA
Morocco
Prior art keywords
tumors
diagnostics
treatments
methods
diagnosing
Prior art date
Application number
MA31315A
Other languages
English (en)
Inventor
Megan Baldwin
Napoleone Ferrara
Hans-Peter Gerber
Farbod Shojaei
Cuiling Zhong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA30348B1 publication Critical patent/MA30348B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)

Abstract

Diagnostics et traitements de tumeurs L'invention concerne des procédés permettant de traiter le cancer par des thérapies de combinaison qui comportent des anticorps anti-VEGF. L'invention concerne également des procédés permettant de diagnostiquer des tumeurs résistantes.
MA31315A 2006-03-29 2008-10-20 Diagnostics et traitements de tumeurs MA30348B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78772006P 2006-03-29 2006-03-29

Publications (1)

Publication Number Publication Date
MA30348B1 true MA30348B1 (fr) 2009-04-01

Family

ID=38564192

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31315A MA30348B1 (fr) 2006-03-29 2008-10-20 Diagnostics et traitements de tumeurs

Country Status (19)

Country Link
US (2) US20070264193A1 (fr)
EP (1) EP1999151A2 (fr)
JP (1) JP2009531463A (fr)
KR (1) KR20080106946A (fr)
CN (1) CN101448856A (fr)
AR (1) AR060228A1 (fr)
AU (1) AU2007233237A1 (fr)
BR (1) BRPI0709425A2 (fr)
CA (1) CA2647430A1 (fr)
CL (1) CL2007000876A1 (fr)
CR (1) CR10325A (fr)
IL (1) IL193842A0 (fr)
MA (1) MA30348B1 (fr)
MX (1) MX2008012279A (fr)
NO (1) NO20084546L (fr)
RU (1) RU2008142775A (fr)
TW (1) TW200806322A (fr)
WO (1) WO2007115045A2 (fr)
ZA (1) ZA200807590B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US20100196509A1 (en) 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
EP2121757A2 (fr) * 2007-02-21 2009-11-25 Ablynx N.V. Séquences d'acides aminés dirigées contre le facteur de croissance de l'endothélium vasculaire et polypeptides comprenant ces séquences, pour le traitement de troubles et de maladies se caractérisant par une angiogenèse pathologique ou une néovascularisation
WO2011063161A2 (fr) 2009-11-20 2011-05-26 The Regents Of The University Of California Protéine 2 de membrane épithéliale (emp2) et vitréorétinopathie proliférative (pvr)
EP3115469B1 (fr) * 2007-11-19 2020-04-29 Celera Corporation Marqueurs du cancer du poumon et utilisations de ceux-ci
WO2009075768A2 (fr) * 2007-12-07 2009-06-18 Children's Hospital Of Orange County Dispositif et procédé optiques pour essai de chémosensibilité en temps réel
EP2262494A2 (fr) * 2008-02-29 2010-12-22 The Board Of Trustees Of The Leland Stanford Junior University Inhibition de la croissance tumorale post-radique par un inhibiteur de la vasculogenèse
WO2010017083A1 (fr) * 2008-08-04 2010-02-11 Wayne State University Procédés de traitement du cancer par des anticorps cd11b
CN102137939A (zh) * 2008-08-29 2011-07-27 霍夫曼-拉罗奇有限公司 不依赖vegf的肿瘤的诊断和治疗
WO2010046889A1 (fr) * 2008-10-23 2010-04-29 Quark Pharmaceuticals, Inc. Procédés de distribution d'arnsi à des cellules de moelle osseuse et leurs utilisations
US9498431B2 (en) 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
BRPI0918211A2 (pt) * 2008-12-23 2015-12-08 Genentech Inc métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf
US7615353B1 (en) 2009-07-06 2009-11-10 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
NZ597531A (en) * 2009-07-31 2014-05-30 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
EP2464744A1 (fr) * 2009-08-14 2012-06-20 F. Hoffmann-La Roche AG Marqueurs biologiques destinés à suivre la réponse d'un patient à des antagonistes des vegf
US7736861B1 (en) 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
EP2536432B1 (fr) * 2010-02-19 2018-08-08 Cornell University Procédé pour traiter des maladies démyélinisantes auto-immunes et d'autres maladies auto-immunes ou inflammatoires
JP5852968B2 (ja) * 2010-02-19 2016-02-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 上皮膜タンパク質２（ｅｍｐ２）結合試薬および眼疾患治療におけるその使用
KR101313184B1 (ko) * 2010-06-24 2013-09-30 한국표준과학연구원 질병 지표 검출 키트 및 질병 지표 검출 방법
KR20140068877A (ko) * 2011-08-17 2014-06-09 제넨테크, 인크. 불응성 종양에서의 혈관신생의 억제
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
RU2502471C9 (ru) * 2012-08-21 2015-04-20 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ оценки соответствия размеров селезенки норме или отклонению от нее у детей методом ультразвуковой диагностики
EP2741086A1 (fr) * 2012-12-06 2014-06-11 Ludwig Boltzmann Gesellschaft Procédé pour mesurer la coagulation d'échantillons de sang à l'aide de tests visco-élastiques (VET)
WO2014127785A1 (fr) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
US20160030558A1 (en) * 2013-03-13 2016-02-04 Health Research, Inc. Enhancement of vaccines
RU2546105C1 (ru) * 2014-04-29 2015-04-10 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ оценки методом ультразвуковой диагностики соответствия размеров селезенки норме или отклонению от нее у детей от 3 до 15 лет
WO2018078158A1 (fr) * 2016-10-31 2018-05-03 Hexal Ag Préparation d'anticorps
EP3826683A4 (fr) * 2018-07-24 2022-04-13 So Young Life Sciences Corporation Utilisation de liposomes permettant la transmission d'une protéine et d'un gène codant pour la protéine à une cellule vivante
US20200347449A1 (en) * 2019-05-01 2020-11-05 The Broad Institute, Inc. Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
CN112946291A (zh) * 2019-12-10 2021-06-11 上海交通大学医学院附属仁济医院 Fgf18在制备诊断和预测卵巢癌试剂中的应用及fgf18化学发光检测试剂盒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (fr) * 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
DE4422551C1 (de) * 1994-06-28 1995-07-27 Daimler Benz Ag Durch Servomotor unterstützte Zahnstangenlenkung
US5871697A (en) * 1995-10-24 1999-02-16 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
KR100816621B1 (ko) * 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP1187633A4 (fr) * 1999-04-08 2005-05-11 Arch Dev Corp Utilisation d'anticorps anti-vegf pour accentuer le rayonnement lors d'une therapie anticancereuse
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
AU784231B2 (en) * 2000-06-23 2006-02-23 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
AU2003215163A1 (en) * 2002-02-12 2003-09-04 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
UA101945C2 (uk) * 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
WO2005044853A2 (fr) * 2003-11-01 2005-05-19 Genentech, Inc. Anticorps anti-vegf
US20060009360A1 (en) * 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition

Also Published As

Publication number Publication date
CA2647430A1 (fr) 2007-10-11
MX2008012279A (es) 2008-10-08
CL2007000876A1 (es) 2008-02-08
CN101448856A (zh) 2009-06-03
CR10325A (es) 2008-12-03
AU2007233237A1 (en) 2007-10-11
IL193842A0 (en) 2011-08-01
NO20084546L (no) 2008-12-23
WO2007115045A3 (fr) 2008-04-03
ZA200807590B (en) 2009-11-25
KR20080106946A (ko) 2008-12-09
WO2007115045A2 (fr) 2007-10-11
TW200806322A (en) 2008-02-01
RU2008142775A (ru) 2010-05-10
BRPI0709425A2 (pt) 2011-07-12
AR060228A1 (es) 2008-06-04
US20100239568A1 (en) 2010-09-23
EP1999151A2 (fr) 2008-12-10
JP2009531463A (ja) 2009-09-03
US20070264193A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
MA30348B1 (fr) Diagnostics et traitements de tumeurs
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
MA31150B1 (fr) Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
EP1912674B8 (fr) Molécules d'anticorps fv à chaîne unique bispécifiques et procédés d'utilisation de celles-ci
IL184617A (en) Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
NZ592215A (en) c-MET ANTIBODIES
MA30654B1 (fr) Therapie tumorale avec anticorps anti-vegf
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
MY191348A (en) Antibodies and derivatives thereof
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
LTPA2015052I1 (lt) Žmogaus monokloniniai antikūnai, skirti užprogramuotai mirčiai 1 (pd-1) ir būdai, skirti vėžio gydymui, naudojant anti-pd-1 antikūnus vienus arba derinyje su kitais imunoterapiniais agentais
WO2010059969A3 (fr) Thérapie antiangiogenèse pour le traitement du cancer du sein
TW200716141A (en) Compositions and methods for treatment for neoplasms
GB0724532D0 (en) Trail variants for treating cancer
MY157173A (en) Modified humanised anti-interleukin-18
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
WO2007103373A3 (fr) Compositions et procédés pour le traitement de troubles immunoinflammatoires
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
UA106771C2 (uk) Моноклональні антитіла до прогастрину та їх використання
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
WO2008034076A3 (fr) Utilisation de cyclophosphamide à doses élevées en combinaison avec des thérapeutiques d'immunisation dans le traitement anticancer
TW200603828A (en) Treatment of disorders
MX2009006034A (es) Anticuerpos antagonistas contra ephb3.